Literature DB >> 8780603

Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection.

S E Ohmit1, F W Moler, A S Monto, A S Khan.   

Abstract

Ribavirin was approved in early 1986 for treatment of illness associated with respiratory syncytial virus (RSV) infection in hospitalized children; however, the value of its use remains controversial. This investigation was undertaken to describe ribavirin utilization and to evaluate the effectiveness of ribavirin in reducing the period of hospitalization. All children with laboratory-confirmed RSV infection, hospitalized over seven epidemic periods at a single institution, were identified. Characteristics from the medical records of the 768 children and their course of hospitalization were evaluated as determinants of treatment with ribavirin. Very young age as well as diagnoses of congenital heart disease, certain pulmonary conditions, and failure to thrive were all significantly related to increased likelihood of treatment. Children requiring intensive care were likely to be treated; however, the most critically ill children, those who required mechanical ventilation, were not treated. Although these results were in keeping with treatment guidelines for the use of ribavirin, actual utilization declined significantly over the course of the evaluation. The effect of ribavirin treatment on the duration of hospitalization among children with community-acquired infection was evaluated in a multivariate model, which controlled for the effects of underlying conditions, measures of illness severity, and epidemic year. This analysis failed to demonstrate a benefit for ribavirin in reducing length of stay; in fact, ribavirin treatment was significantly associated with prolonged hospitalization. It was not likely that the explanation for ribavirin's association with prolonged hospitalization was that the most seriously ill children were treated; however, it was not possible to determine whether this association was due to an adverse effect of treatment or resulted from a perceived need to complete the course of therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8780603     DOI: 10.1016/0895-4356(96)00137-0

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  4 in total

1.  Discovery of a Potent Dual Inhibitor of Wild-Type and Mutant Respiratory Syncytial Virus Fusion Proteins.

Authors:  Toru Yamaguchi-Sasaki; Seiken Tokura; Yuya Ogata; Takanori Kawaguchi; Yutaka Sugaya; Ryo Takahashi; Kanako Iwakiri; Tomoko Abe-Kumasaka; Ippei Yoshida; Kaho Arikawa; Hiroyuki Sugiyama; Kosuke Kanuma
Journal:  ACS Med Chem Lett       Date:  2020-04-10       Impact factor: 4.345

2.  RFI-641, a potent respiratory syncytial virus inhibitor.

Authors:  Clayton C Huntley; William J Weiss; Anna Gazumyan; Aron Buklan; Boris Feld; William Hu; Thomas R Jones; Timothy Murphy; Antonia A Nikitenko; Bryan O'Hara; Gregory Prince; Susan Quartuccio; Yuri E Raifeld; Philip Wyde; John F O'Connell
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

Review 3.  Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children.

Authors:  Eric A F Simões; Louis Bont; Paolo Manzoni; Brigitte Fauroux; Bosco Paes; Josep Figueras-Aloy; Paul A Checchia; Xavier Carbonell-Estrany
Journal:  Infect Dis Ther       Date:  2018-02-22

Review 4.  RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations.

Authors:  Richard L Wasserman; Benjamin N Greener; James Mond
Journal:  Expert Rev Clin Immunol       Date:  2017-10-16       Impact factor: 4.473

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.